ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
January 05, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
EHang Announces Strategic Partnership and Investment with Qingdao West Coast New Area
December 23, 2022 08:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, Dec. 23, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Holdings Limited Announces Appointment of Nick Ning Yang as New Independent Director
December 05, 2022 07:27 ET
|
EHang Holdings Limited
GUANGZHOU, China, Dec. 05, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang to Report Third Quarter 2022 Unaudited Financial Results on Friday, December 2, 2022
November 21, 2022 07:30 ET
|
EHang Holdings Limited
GUANGZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang and HAECO Group Explore Partnership in Advanced Air Mobility
October 31, 2022 08:44 ET
|
EHang Holdings Limited
GUANGZHOU, China, Oct. 31, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
October 04, 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
EHang Announces Progress in EH216-S Type Certification Process as It Enters into More In-Depth Review Phase
September 30, 2022 10:07 ET
|
EHang Holdings Limited
GUANGZHOU, China, Sept. 30, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2022 17:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
EHang Reports Second Quarter 2022 Unaudited Financial Results
August 18, 2022 05:00 ET
|
EHang Holdings Limited
– Total Revenues Up 152.5% QoQ– High Quarterly Gross Margin of 67.1%– Indicative Facilities of RMB1 Billion by Agricultural Bank of China Guangzhou Branch– Increasing Deliveries in China and...